Table 1.
Preoperative characteristics in patients undergoing robot-assisted precision prostatectomy, n=8 (MPP; IDEAL stage 1/2a)
| PREOPERATIVE PARAMETERS | |
| Demographic details | |
| Age in years; median (IQR) | 54 (52–57) |
| BMI in kg/m2; median (IQR) | 29 (24.7–34.3) |
| Comorbidities; n (%) | |
| Diabetes mellitus | 2 (25) |
| Hypertension | 1 (12.5) |
| COPD/Asthma | 0 (0) |
| Cerebrovascular disease | 2 (25) |
| Prior abdominal surgeries | 0 (0) |
| American Society of Anesthesiologists score; median (IQR) | 2 (1–3) |
| Tumor characteristics | |
| PSA in ng/mL; median (IQR) | 4.4 (3.8–6.1) |
| Clinical tumor stage; n (%) | |
| cT1 | 5 (62.5) |
| cT2a | 3 (37.5) |
| Transrectal ultrasound-guided biopsy (12–16 cores) | |
| Highest Gleason score; n (%) | 5 (62.5) |
| 3+3 | 4 (50) |
| 3+4 | 4 (50) |
| Number of positive cores; median (IQR) | 3.5 (2–5) |
| Percent core positivity; median (IQR) | 29.2 (16.7–41.7) |
| Unilateral disease (core positivity limited to one side); n (%) | 6 (75) |
| Preoperative IIEF-5 score; median (IQR) | 24 (23–25) |
| Preoperative IPSS score; median (IQR) | 3 (2.5–3.5) |
BMI, body mass index; COPD, chronic obstructive pulmonary disease; IIEF-5, International Index of Erectile Function; IPSS, International Prostate Symptom Score; IQR, IQR range; PSA, prostate specific antigen.